Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles + Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

About Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles + Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles + Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Merkel Cell Carcinoma, Stage I. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07387198. Target conditions include Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy.

What happened to similar drugs?

0 of 1 similar drugs in Merkel Cell Carcinoma, Stage I were approved

Hype Score Breakdown